MedTrace Logo

Xarelto on Prevention of Stroke and Non-central Nervous System Systemic Embolism in Patients With Non-valvular Atrial Fibrillation in China: A Non-interventional Study

NCT02784717 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3055

Last updated 2020-09-03

No results posted yet for this study

Summary

This non-interventional field study will investigate rivaroxaban under clinical practice conditions for stroke prevention and for prevention of non-CNS systemic embolism in patients with non-valvular atrial fibrillation in China.

Conditions

Interventions

DRUG

Rivaroxaban (Xarelto, BAY 59-7939)

Decision regarding dose and duration of treatment made at the discretion of the attending investigator.

Sponsors & Collaborators

  • Janssen Scientific Affairs, LLC

    collaborator INDUSTRY

  • Bayer

    lead INDUSTRY

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-05-11
Primary Completion
2019-02-21
Completion
2019-09-24

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02784717 on ClinicalTrials.gov